Home : Company : Q News : Quantimetrix Corporation enriches website content for Lipoprint

Quantimetrix Corporation enriches website content for Lipoprint

February 12, 2015

FOR IMMEDIATE RELEASE: (February 12, 2015)
Quantimetrix Corporation enriches website content for Lipoprint
Pioneer of liquid laboratory control stabilization technology and Lipoprint Lipoprotein Subfractions Testing System.

Redondo Beach, CA, February 12, 2015 – Quantimetrix Corporation, handcrafting world-class, ready-to-use laboratory quality control products for urinalysis, general chemistry, specialty chemistry, and whole blood, relaunches extended content-rich Lipoprint® Lipoprotein Subfractions Testing System information on their website – quantimetrix.com

Last summer, in Chicago at the 2014 AACC/ASCLS, Quantimetrix presented an important scientific poster entitled, LDL Subfractions Analysis in Pro-atherogenic Dyslipidemia; N. Muñiz, E. Nuñez, M. Rivera, M. Ban – Quantimetrix, Redondo Beach, CA. “We were met with overwhelming support for our scientific findings from the cardiovascular research community.” said the jubilant Nemo Muñiz, Director of Electrophoresis for Quantimetrix. “There has been so much confusion within this community about the new cholesterol treatment recommendations for primary and secondary ASCVD risk management and with this poster and hundreds more from researchers using our Lipoprint System, we’re finally able to be heard above the old, outdated chatter,” he added.

For more than 20 years, since the introduction of Lipoprint, Quantimetrix has been on the forefront of personalized diagnostic cardiology research and responding to the needs of this scientific community. The enriched website content supports these goals, and provides visitors with valuable information as well as a Lipoprint System video overview.

Monty Ban, President of Quantimetrix, said, “We thought it was time to spread the word about how Lipoprint may provide doctors with more tools to assess this growing health emergency and opening up the conversation for discovery of new ways to treat cardiac patients.”

Quantimetrix invites you to visit this enriched content at